German ADC specialist Tubulis closed a $361 million Series C to advance its next‑generation antibody‑drug conjugates into clinical development and expand manufacturing capacity. Investors emphasized Tubulis’ proprietary linker and payload chemistry as the drivers for the large round, which positions the company for accelerated clinical milestones. Separately, French startup Adcytherix secured €105 million (about US$122 million) in a Series A to take its lead ADC program into the clinic next year. The financing is intended to support IND‑enabling studies and early clinical development. Both financings signal renewed investor appetite for ADC platforms and therapeutics as the modality shows promise in earlier disease settings. For investors and founders, these rounds mark a return of large private financings for therapeutic platforms with differentiated chemistry and development readiness.